Emcure Pharmaceuticals Limited (EMCURE) Share Price
NSE · Healthcare · Drug Manufacturers - Specialty & Generic · ISIN INE168P01015
Key metrics
- Market Cap
- ₹35,254 Cr
- P/E Ratio
- 34.83
- EPS
- 53.35
- Book Value
- 262.5
- P/B Ratio
- 7.03
- ROE
- 18.57%
- ROCE
- 21.14%
- Debt / Equity
- 0.31
- Net Margin
- 10.04%
- Revenue Growth
- 16.56%
- Profit Growth
- 35.67%
- Dividend Yield
- 0.2%
- 52W High
- ₹2,048.00
- 52W Low
- ₹1,260.00
- Market Cap Band
- large cap
- Face Value
- 10
Ratios computed from the annual results period ending 2026-03-31.
About Emcure Pharmaceuticals Limited
Emcure Pharmaceuticals Limited provide quality and affordable healthcare solutions worldwide. It offers products in various therapeutic areas, such gynecology, anti-infectives, pain/analgesics, Vitamins, Minerals & Nutrients, blood-related, oncology, respiratory, HIV antivirals, gastro, anti-diabetic, neuro, and cardiovascular. It provides its products under Orofer XT, Tenectase, Pause, Metpure XL, Vylda, Vitanova, and Proxym brand names. Emcure Pharmaceuticals Limited has a strategic partnership with Novo Nordisk India Pvt Ltd. for the development and commercialization of Poviztra, a semaglutide injection for weight loss. Emcure Pharmaceuticals Limited was incorporated in 1981 and is based in Pune, India.
- Headquarters
- Pune, India
- Employees
- 6,914
- Promoter Holding
- 81.76%
The full Emcure Pharmaceuticals Limited analysis
Create a free account to open the complete EMCURE deep-dive — fourteen tabs of fundamental, technical, institutional and ownership data.
- 10-year financialsIncome statement, balance sheet and cash flow, year by year.
- Valuation & fair valueFair-value estimates, quality scores and a value grade.
- Charts & technicalsCandlestick charts, RSI, MACD, Supertrend and detected patterns.
- Shareholding historyPromoter, FII, DII and public holdings across every quarter.
- Ace investor holdingsWhich well-known investors hold it, and how their stake changed.
- Deals & insider tradesBulk and block deals, insider transactions and mutual-fund holdings.